Last reviewed · How we verify
OPTI-FREE® RepleniSH®
OPTI-FREE® RepleniSH® is a marketed product developed by Massachusetts Eye and Ear Infirmary, currently holding a position in the eye care market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive advantage. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | OPTI-FREE® RepleniSH® |
|---|---|
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens (NA)
- Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations (NA)
- Clinical Characterization of an Investigational Frequent Replacement Daily Wear Silicone Hydrogel Sphere Contact Lens (NA)
- Clinical Characterization of an Investigational Soft Silicone Hydrogel Contact Lens (NA)
- Clinical Performance Assessment of a Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lens (NA)
- Performance and Safety of Silicone Hydrogel Soft Contact Lenses (NA)
- Clinical Biocompatibility Evaluation of Contact Lens Coatings (NA)
- Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPTI-FREE® RepleniSH® CI brief — competitive landscape report
- OPTI-FREE® RepleniSH® updates RSS · CI watch RSS
- Massachusetts Eye and Ear Infirmary portfolio CI